San Diego, September 25, 2014 – GenomeDx Biosciences today announced that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostic laboratory testing. The agreement includes GenomeDx Biosciences’ participation in the MultiPlan Network, expanding access to the Decipher® Prostate Cancer Classifier to health plan members who access the more than 500,000 providers participating in the MultiPlan Network.
The Decipher prostate cancer classifier directly measures a patient’s biological risk of developing metastatic prostate cancer. Together with coverage from existing networks, the contract brings coverage of the Decipher prostate cancer test to over 190 million lives.
“We continue to pursue signing new PPO network agreements to further improve patient access to Decipher. Decipher has been demonstrated in studies to show how aggressive a patients’ prostate cancer is and, therefore, may help patients’ physicians make more informed decisions about the course of treatment following prostate cancer surgery,” said Doug Dolginow, MD, CEO of GenomeDx.
About Decipher
The Decipher® Prostate Cancer Classifier directly measures a patient’s biological risk of developing metastatic prostate cancer. By assessing the activity of multiple genomic markers associated with metastatic disease, Decipher provides information about the aggressiveness of a patient’s tumor – information distinct from that provided by PSA and other clinical tools. Already tested in over 2,000 patients, Decipher continues to demonstrate that it can accurately predict aggressive disease and direct treatment decisions for men with prostate cancer.
Decipher is covered by multiple private insurance plans and is available to eligible US patients through their physicians. To learn more about ordering the Decipher test please visit www.deciphertest.com.
About GenomeDx
GenomeDx Biosciences is focused on transforming patient management by putting usable genomic information in the hands of patients and their physicians. GenomeDx has developed the Decipher® Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
Learn more at www.genomedx.com
About MultiPlan
MultiPlan, Inc. is the industry’s most comprehensive provider of healthcare cost management solutions.
The company provides a single gateway to a host of network- and analytics-based solutions for managing the financial risks associated with healthcare claims. Clients include insurers, health plans, third-party administrators, self-funded employers, HMOs and other entities that pay medical bills in the commercial healthcare, government, workers compensation and auto medical markets.
Learn more at www.Multiplan.com